摘要:
The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
摘要:
The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
摘要:
The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions. Methods for using the scFc molecules of the present inventions are provided
摘要:
The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
摘要:
The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
摘要:
We claim the proteinase inhibitors comprising a Kunitz domain, wherein the Kunitz domain comprises amino acid residues 57–107 of SEQ ID NO: 2. We also claim a fusion protein comprising said Kunitz domain. In addition, we claim a method of inhibiting protease degradation or protease activity in a composition which contains plasma proteins and proteases. The proteinase inhibitors is used as components of cell culture media in cell culture process, and as inhibitors of protease-mediated degradation of plasma proteins in protein purification.
摘要翻译:我们要求包含Kunitz结构域的蛋白酶抑制剂,其中Kunitz结构域包含SEQ ID NO:2的氨基酸残基57-107。我们还要求包含所述Kunitz结构域的融合蛋白。 此外,我们提出了在含有血浆蛋白和蛋白酶的组合物中抑制蛋白酶降解或蛋白酶活性的方法。 蛋白酶抑制剂在细胞培养过程中用作细胞培养基的组分,并且作为蛋白质介导的蛋白质纯化中血浆蛋白质降解的抑制剂。
摘要:
Proteins consisting of two PDGF-D polypeptide chains, polynucleotides encoding the polypeptides, and materials and methods for making the proteins are disclosed. Each of the polypeptide chains consists of, from amino terminus to carboxyl terminus, the following operably linked segments: P1-P2-h-CH2-CH3; P1-P2-CH2-CH3; h-CH2-CH3-P2-P1; or CH2-CH3-P2-P1. Within these polypeptide chains, P1 is a first polypeptide segment as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365–370, inclusive; P2 is a second polypeptide segment consisting of from 4 to 20 amino acid residues; h is an immunoglobulin hinge region or portion thereof; and CH2 and CH3 are CH2 and CH3 domains of an immunoglobulin heavy chain, respectively. Within the protein, the two polypeptide chains are joined by one or more disulfide bonds, each of the chains is optionally glycosylated, and the protein binds to and activates cell-surface PDGF receptors.
摘要翻译:公开了由两个PDGF-D多肽链组成的蛋白质,编码多肽的多核苷酸,以及用于制备蛋白质的材料和方法。 每个多肽链由氨基末端至羧基末端组成以下可操作连接的片段:P1-P2-h-C H-2-C 3 H 3; P1-P2-C H-2-C H 3; H-C H-2-C 3-P2-P1; 或C H 2 -C 3 -PO-P-2。 在这些多肽链中,P1是从氨基酸x至氨基酸y的SEQ ID NO:2或SEQ ID NO:4所示的第一个多肽区段,其中x是246至258的整数,包括端值,y是 整数为365-370,含 P2是由4至20个氨基酸残基组成的第二多肽区段; h是免疫球蛋白铰链区域或其部分; 和C H 2和C H 3是免疫球蛋白重链的C H 2 H 2和C 3 H 3结构域 , 分别。 在蛋白质内,两条多肽链通过一个或多个二硫键连接,每个链任选被糖基化,并且蛋白质结合并激活细胞表面PDGF受体。
摘要:
Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要:
A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要:
The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.